These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24064355)

  • 1. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Mackey HM; Bengtsson T
    Contemp Clin Trials; 2013 Nov; 36(2):664-72. PubMed ID: 24064355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.
    Frueh FW
    Pharmacogenomics; 2009 Jul; 10(7):1077-81. PubMed ID: 19604080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two clinical trial designs to examine personalized treatments for psychiatric disorders.
    Leon AC
    J Clin Psychiatry; 2011 May; 72(5):593-7. PubMed ID: 20673550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An industry statistician's perspective on PHC drug development.
    Fridlyand J; Yeh RF; Mackey H; Bengtsson T; Delmar P; Spaniolo G; Lieberman G
    Contemp Clin Trials; 2013 Nov; 36(2):624-35. PubMed ID: 23648396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical perspectives of personalized healthcare in oncology.
    Hodgson DR; Wellings R; Harbron C
    N Biotechnol; 2012 Sep; 29(6):656-64. PubMed ID: 22426411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing risk and improving efficacy of clinical trials: the adaptive design.
    Dangi-Garimella S
    Am J Manag Care; 2014 Aug; 20(11 Spec No.):E8. PubMed ID: 25618150
    [No Abstract]   [Full Text] [Related]  

  • 11. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
    Weir CJ; Walley RJ
    Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints.
    He P
    Contemp Clin Trials; 2014 Jul; 38(2):333-7. PubMed ID: 24948401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.
    Agur Z; Elishmereni M; Kheifetz Y
    Wiley Interdiscip Rev Syst Biol Med; 2014; 6(3):239-53. PubMed ID: 24604755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.